MedPath

To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

Phase 3
Completed
Conditions
Osteoarthritis
Interventions
Registration Number
NCT02596451
Lead Sponsor
Glenmark Pharmaceuticals Ltd. India
Brief Summary

This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium topical gel) 1% (Novartis Consumer Health, Inc) in Patients with Osteoarthritis (OA) of the Knee

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1164
Inclusion Criteria
  1. Healthy male or non-pregnant female aged ≥ 35 years with a clinical diagnosis of OA of the knee according to the American College of Rheumatology (ACR) criteria.
  2. OA Symptoms for at least 6 months prior to screening.
  3. Baseline Western Ontario McMaster Osteoarthritis (WOMAC) pain subscale of > 9 on a 20 point scale for the target knee immediately prior to randomization.
Exclusion Criteria
  1. History of OA pain in the contralateral knee requiring medication within 1 year prior to screening.
  2. History of secondary OA, rheumatoid arthritis, chronic inflammatory disease (e.g., colitis) or fibromyalgia.
  3. History of gastrointestinal bleeding or peptic ulcer disease.
  4. Known allergy to aspirin or nonsteroidal anti-inflammatory drug (NSAID).
  5. Use of anticoagulants, ACE-inhibitors, cyclosporine, diuretics, lithium, or methotrexate prior to 30 days of screening.
  6. Concomitant use of systemic corticosteroids, topical corticosteroids, or immunosuppressive drugs or their use prior to 30 days of screening.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Voltaren® GelVoltaren® Gelapply gel to the target knee
Diclofenac Sodium gel, 1%Diclofenac Sodium gel, 1%apply gel to the target knee
PlaceboPlaceboapply gel to the target knee
Primary Outcome Measures
NameTimeMethod
Absolute Change in the Total WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Subscale Score for the Target KneeBaseline and week 4

The total WOMAC Pain Subscale score was determined by summing the individual scores from each of the five questions using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4) comprising the WOMAC Pain Subscale Rating for the Target Knee.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (44)

Glenmark Investigational Site 30

🇺🇸

Carmichael, California, United States

Glenmark Investigational Site 34

🇺🇸

Dallas, Texas, United States

Glenmark Investigational Site 31

🇺🇸

Anaheim, California, United States

Glenmark Investigational Site 38

🇺🇸

Wichita, Kansas, United States

Glenmark Investigational Site 19

🇺🇸

Miami, Florida, United States

Glenmark Investigational Site 28

🇺🇸

Miami, Florida, United States

Glenmark Investigational Site 39

🇺🇸

Nashville, Tennessee, United States

Glenmark Investigational Site 29

🇺🇸

San Antonio, Texas, United States

Glenmark Investigational Site 6

🇺🇸

San Antonio, Texas, United States

Glenmark Investigational Site 40

🇺🇸

Miami, Florida, United States

Glenmark Investigational Site 11

🇺🇸

West Palm Beach, Florida, United States

Glenmark Investigational Site 5

🇺🇸

Mesa, Arizona, United States

Glenmark Investigational Site 3

🇺🇸

Miami Lakes, Florida, United States

Glenmark Investigational Site 32

🇺🇸

Miami, Florida, United States

Glenmark Investigational Site 10

🇺🇸

Fort Lauderdale, Florida, United States

Glenmark Investigational Site 37

🇺🇸

Ormond Beach, Florida, United States

Glenmark Investigational Site 36

🇺🇸

Knoxville, Tennessee, United States

Glenmark Investigational Site 22

🇺🇸

Saginaw, Michigan, United States

Glenmark Investigational Site 21

🇺🇸

Anaheim, California, United States

Glenmark Investigational Site 42

🇺🇸

Carlsbad, California, United States

Glenmark Investigational Site 1

🇺🇸

Anaheim, California, United States

Glenmark Investigational Site 26

🇺🇸

Canoga Park, California, United States

Glenmark Investigational Site 33

🇺🇸

Cerritos, California, United States

Glenmark Investigational Site 25

🇺🇸

El Cajon, California, United States

Glenmark Investigational Site 24

🇺🇸

La Mesa, California, United States

Glenmark Investigational Site 2

🇺🇸

Pasadena, California, United States

Glenmark Investigational Site 13

🇺🇸

Rancho Cucamonga, California, United States

Glenmark Investigational Site 15

🇺🇸

Miami, Florida, United States

Glenmark Investigational Site 18

🇺🇸

West Palm Beach, Florida, United States

Glenmark Investigational Site 43

🇺🇸

Newburgh, Indiana, United States

Glenmark Investigational Site 9

🇺🇸

Englewood, Ohio, United States

Glenmark Investigational Site7

🇺🇸

Altoona, Pennsylvania, United States

Glenmark Investigational Site 14

🇺🇸

Saint Louis, Missouri, United States

Glenmark Investigational Site 23

🇺🇸

Beaumont, Texas, United States

Glenmark Investigational Site 20

🇺🇸

Bryan, Texas, United States

Glenmark Investigational Site 4

🇺🇸

Lampasas, Texas, United States

Glenmark Investigational Site 35

🇺🇸

Houston, Texas, United States

Glenmark Investigational Site 44

🇺🇸

Houston, Texas, United States

Glenmark Investigational Site 16

🇺🇸

Charlottesville, Virginia, United States

Glenmark Investigational Site12

🇺🇸

Midlothian, Virginia, United States

Glenmark Investigational Site 41

🇺🇸

Hialeah, Florida, United States

Glenmark Investigational Site 8

🇺🇸

Evanston, Illinois, United States

Glenmark Investigational Site 27

🇺🇸

Sacramento, California, United States

Glenmark Investigational Site 17

🇺🇸

New Orleans, Louisiana, United States

© Copyright 2025. All Rights Reserved by MedPath